• Users Online: 101
  • Print this page
  • Email this page

 Table of Contents  
Year : 2012  |  Volume : 2  |  Issue : 2  |  Page : 39-40

This issue at a glance

Department of Ophthalmology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

Date of Web Publication19-May-2012

Correspondence Address:
Rong Kung Tsai
Department of Ophthalmology and Visual Science, College of Medicine, Tzu Chi University, Hualien, Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.tjo.2012.04.003

Rights and Permissions

How to cite this article:
Tsai RK. This issue at a glance. Taiwan J Ophthalmol 2012;2:39-40

How to cite this URL:
Tsai RK. This issue at a glance. Taiwan J Ophthalmol [serial online] 2012 [cited 2021 Jan 21];2:39-40. Available from: https://www.e-tjo.org/text.asp?2012/2/2/39/203719

Regenerative medicine, including neuroprotection, gene therapy, and cell therapy, is a promised land for many ocular degenerative diseases such as retinitis pigmentosa and macular degeneration. A search of the literature will reveal a large number of relevant reports, but the milk and honey in the promised land is not available yet in clinical use. The question is when our patients will be able to receive any benefit from the cutting-edge of new treatments. The first report of human embryonic stem cell (hESC)-derived cells transplanted into patients with Stargardt’s macular dystrophy or dry age-related macular degeneration was recently published.[1] Over a very short follow-up period of 4 months, vision seemed to have improved in both patients, and the hESC-derived retinal pigment epithelium cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection.[1] So far, the outcome has been promising and safe—good news indeed.

In this issue of the Taiwan Journal of Ophthalmology (TJO), Kaplan and Fernandez de Castro summarize recent advances in the field and the potential they have for the treatment of retinitis pigmentosa and other retinal degenerations. Yin and Lee also report their marvelous animal studies of cell therapy in Royal College of Surgeons rats and in minipigs with light induced-degeneration. Their functional investigations show that transplantation of retinal stem cells could delay the progress of retinal degeneration in Royal College of Surgeons rats and light-induced retinal degeneration in minipigs. These authors also observed that the transplanted retinal stem cells had an effect on the processes of dedifferentiation and redifferentiation of regional Müller cells in transforming into other retinal neurons such as retinal pigment epithelium cells or photo-receptors. Readers of TJO may obtain up-to-date information related to cell therapy in ophthalmology from both review articles.

Inflammation plays an important role in age-related macular degeneration (ARMD). Sheu et al have identified the inflammation-associated single nucleotide polymorphisms that modulate ARMD risk. They found a significant association between carriers with polymorphisms of interleukin-4 590 genotypes and the development ARMD. ARMD is a complex disease reflecting interactions between genetics and the microenvironment; this report may contribute to our understanding of the pathogenesis of ARMD.

Lai et al report visual outcomes after epiretinal membrane surgery with or without internal limiting membrane peeling. Although the visual outcome and macular thickness improved equally in both groups, the incidence of recurrence was lower in the group who had peeling of the internal limiting membrane. Recurrence of an epiretinal membrane was associated with a poor prognosis.

In a retrospective report of retinopathy of prematurity in infants with low birthweight, Liu et al concluded that lower gestational age, lower body weight at birth, a greater degree of respiratory distress syndrome, prolonged use of oxygen, and a lack of maternal history of antenatal steroid use are risk factors for the severity of retinopathy of prematurity.

There is still no consensus about the most effective treatment for polypoidal choroidal vasculopathy. In a retrospective study in this issue of TJO, Lee et al report their treatment efficacy of photodynamic therapy with verteporfin in patients suffering from polypoidal choroidal vasculopathy. After a follow-up lasting more than 3 years, they found that the visual improvement after treatment of photodynamic therapy with verteporfin was temporarily significant at 6 months. Further prospective studies with a control group and combined therapy may resolve this issue.

In the case report section, both Chen et al’s article on Duane’s retraction syndrome associated with crocodile tears and hearing loss, and Lee et al’s paper on chiasmal optic neuritis provide good information to expand our clinical understanding.

Once again, the efforts of the editorial board of TJO have been dedicated to providing a high-quality journal for our society members. The journal’s future success can be assured by your participation in submitting your papers to TJO.

  References Top

Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012;379:713–20.  Back to cited text no. 1


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal